StudyFinder
Search Results
Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
Search all categories
484 Study Matches
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure (TEAM-HF)
Nourdine Chakouri, PhD - nourdine.chakouri@abbott.com
NCT06526195
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
• LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
• Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or \<50% of predicted peak VO2 value)
• NYHA Class IIIB or NYHA Class IV
• Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
• Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
• Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group Randomization Criteria:
• Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
• Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
• mean PAP ≥ 30 mmHg.
• The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant. Single Arm Registry Criteria:
• Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
• Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
• mean PAP \<30 mmHg
Exclusion Criteria:
• Subject is \< 18 years of age at the time of informed consent.
• Dependent on IV inotrope in the last 30 days.
• Contra-indications to HM3 LVAS or CardioMEMS HF system.
• Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
• Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
• Existence of ongoing MCS.
• Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
• History of any solid organ transplant.
• Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
• Presence of an active, uncontrolled infection.
• Complex congenital heart disease.
• Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.
• History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\>1 episode) pulmonary embolism and/or deep vein thrombosis.
• Planned VAD or Bi-VAD support prior to enrollment.
• Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:
• An INR ≥ 2.0 not due to anticoagulation therapy
• An eGFR \< 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
• Biopsy proven liver cirrhosis.
• Need for chronic renal replacement therapy.
• History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 \< 30% predicted.
• History of cerebrovascular disease with significant (\> 80%) uncorrected internal carotid stenosis.
• Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
• Any condition other than HF that could limit survival to less than 24 months.
• Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
DEVICE: CardioMEMS HF System, DEVICE: HeartMate 3 Left Ventricular Assist System, OTHER: Guideline Medical Directed Therapy
Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Heart Failure, Left Ventricular Assist Device (LVAD), Guideline Directed Medical Therapy (GDMT), Non-inotrope Dependent, Pulmonary Artery Pressure, Hemodynamic Monitoring, Medical Management, CardioMEMS, HeartMate 3 (HM3), Ambulatory Advanced Heart Failure
I'm interested
Share via email
Show 70 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| A.O.U. Citta della Salute e della Scienza di Torino Turin, Piedmont | Giuditta Cuccuru - (gcuccuru@cittadellasalute.to.it) |
| AKH -Wien Vienna, State of Vienna | Julia Riebandt, MD, PhD - (julia.riebandt@meduniwien.ac.at) |
| Abington Memorial Hospital Abington, Pennsylvania | Colleen Marchand - (colleen.marchand@jefferson.edu) |
| Advocate Health & Hospitals Corporation Oakbrook Terrace, Illinois | Mairead Delaney - (mairead.delaney@aah.org) |
| Allegheny General Hospital Pittsburgh, Pennsylvania | Laurie Machen - (Laurie.MACHEN@ahn.org) |
| Ascension Texas Cardiovascular Austin, Texas | Jennifer Mcsorley - (jennifer.mcsorley@ascension.org) |
| Aurora Medical Group Milwaukee, Wisconsin | Don Lobacz - (donald.lobacz@aah.org) |
| Banner-University Medical Center Phoenix Phoenix, Arizona | |
| Baptist Health Medical Center Little Rock, Arkansas | Victoria Marren - (victoria.marren@baptist-health.org) |
| Baylor University Hospital Dallas, Texas | Shelby Shull - (Shelby.Shull@BSWHealth.org) |
| CHI St. Luke's Health Baylor College of Medicine Medical Center Houston, Texas | Wajeeha Abrar - (Wajeeha.Abrar@bcm.edu) |
| Carolinas Medical Center Charlotte, North Carolina | Dana Amaro - (dana.amaro@atriumhealth.org) |
| Christ Hospital Cincinnati, Ohio | Susanne Pasley - (susanne.pasley@thechristhospital.com) |
| Cleveland Clinic Florida Weston, Florida | Maria Mejia-Gomez - (mejiagm@ccf.org) |
| Deutsches Herzzentrum der Charité Berlin, State of Berlin | Annegret Schneider - (schneider@dhzb.de) |
| Erasmus MC - Thoraxcenter Rotterdam, Holland | Nico Van Den Berg - (n.berg@erasmusmc.nl) |
| Hackensack University Medical Center Hackensack, New Jersey | Manuel Castillo - (Manuel.Castillo@hmhn.org) |
| Henry Ford Hospital Detroit, Michigan | Zack Malouf - (zmalouf1@hfhs.org) |
| Herzzentrum Leipzig GmbH Leipzig, Saxony | Victoria Himstedt - (victoria.himstedt@helios-health-institute.com) |
| Houston Methodist Houston, Texas | Mary Kelly - (makelly@houstonmethodist.org) |
| IKEM Prague Prague, CBohmia | - (martina.kucerova@ikem.cz) |
| Integris Baptist Medical Center Oklahoma City, Oklahoma | Jill Bethany Fife - (bethany.fife@integrishealth.org) |
| Kansas University Medical Center Kansas City, Kansas | Terry Christenson - (tchristenson3@kumc.edu) |
| King Fahad Medical City Riyadh, Riyadh Region | Joud Hewaidi - (jhewaidi@kfmc.med.sa) |
| King Faisal Specialist Hospital Riyadh, Riyadh Region | Luluah Altukhaifi - (laltukaifi@kfshrc.edu.sa) |
| Maine Medical Center Portland, Maine | Monica Palmeri - (monica.palmeri@mainehealth.org) |
| Massachusetts General Hospital Boston, Massachusetts | Bronwen Rees-Weidemann - (brees-wiedemann@mgh.harvard.edu) |
| Mayo Clinic Rochester, Minnesota | Colleen Irlbeck - (Irlbeck.Colleen@mayo.edu) |
| Medical University of South Carolina Charleston, South Carolina | Melissa Lamicq - (Lamicq@musc.edu) |
| Medizinische Hochschule hannover Hanover, | Antje Juergens - (juergens.antje@mh-hannover.de) |
| Minneapolis Heart Institute Minneapolis, Minnesota | Kate Jappe - (Kate.Jappe@allina.com) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Sabrina Sicilia - (ssicilia@montefiore.org) |
| New Mexico Heart Institute Albuquerque, New Mexico | Rebecca Jones - (Rebecca.Jones@lovelace.com) |
| New York-Presbyterian/Columbia University Medical Center New York, New York | Jessica Idumonyi - (joi2102@cumc.columbia.edu) |
| Newark Beth Israel Medical Center Newark, New Jersey | Patel Bhargavi - (bhargavi.patel2@rwjbh.org) |
| North Shore University Hospital Manhasset, New York | Salome Reddy - (seliareddy@northwell.edu) |
| Norton Hospital Louisville, Kentucky | Laurie Michelle Jones - (laurie.jones@nortonhealthcare.org) |
| Oklahoma Heart Institute at Utica Tulsa, Oklahoma | Allyson O'Guin - (allyson.oguin@hillcrest.com) |
| Oregon Health & Science University Portland, Oregon | Ricardo Mendoza - (Mendozri@ohsu.edu) |
| Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania | Amanda Donnangelo - (adonnangelo@pennstatehealth.psu.edu) |
| Piedmont Augusta Hospital Augusta, Georgia | Jennifer Hansen - (jennifer.hansen@piedmont.org) |
| Piedmont Heart Institute Atlanta, Georgia | Andrew Bailey - (Andrew.Bailey1@piedmont.org) |
| Prisma Health Midlands Columbia, South Carolina | Abigail Anderson - (Abigail.Anderson@prismahealth.org) Brooks Ferguson - (Brooks.Ferguson@prismahealth.org) |
| Rigshospitalet Copenhagen, | Christina Moeller - (Christina.Moeller@regionh.dk) |
| Saint Francis Hospital Greenville, South Carolina | Riley Pritzlaff - (rpritzlaff@saintfrancis.com) |
| Scott & White Memorial Hospital Temple, Texas | Rohini Bagewadi - (rohini.bagewadi@bswhealth.org) |
| Shands at the University of Florida Gainesville, Florida | Erikson Walter - (erikson.walter@ufl.edu) |
| Spectrum Health Butterworth Hospital Grand Rapids, Michigan | Stephanie Hanson - (stephanie.hanson@corewellhealth.org) |
| St. Luke's Hospital Cedar Rapids, Iowa | Amanda Huffman - (ahuffman@saint-lukes.org) |
| St. Vincent Hospital Indianapolis, Indiana | Regina Margiotti - (Regina.Margiotti@ascension.org) |
| Sutter Medical Center Sacramento, California | Jessica Mccall - (jessica.mccall@sutterhealth.org) |
| The Cleveland Clinic Foundation Cleveland, Ohio | Barbara Gus - (gusb@ccf.org) |
| The Heart Hospital Baylor Plano Plano, Texas | Shelby McCoy - (shelby.mccoy@bswhealth.org) |
| The Stern Cardiovascular Foundation Memphis, Tennessee | Rishi Bhula - (rishi.bhula@sterncardio.com) |
| UMC Utrecht Utrecht, | Manon Kuikhoven - (m.j.kuikhoven@umcutrecht.nl) |
| UTHealth Memorial Hermann Houston, Texas | Lawana Self - (lawana.self@uth.tmc.edu) |
| University of California at San Francisco San Francisco, California | Tyre Richardson - (tyre.richardson@ucsf.edu) |
| University of Chicago Chicago, Illinois | Kristen Hanauer - (kristen.hanauer@bsd.uchicago.edu) |
| University of Iowa Hospitals & Clinics Iowa City, Iowa | Page Scovel - (Page-scovel@uiowa.edu) |
| University of Kentucky Lexington, Kentucky | |
| University of Nebraska Medical Center Omaha, Nebraska | Ryan Ruskamp - (ryan.ruskamp@unmc.edu) |
| University of North Carolina at Chapel Hill Chapel Hill, North Carolina | Hanna Mixon - (hanna_mixon@med.unc.edu) |
| University of Pennsylvania Philadelphia, Pennsylvania | Emma Markley - (Emma.markley@pennmedicine.upenn.edu) |
| University of Pittsburgh Medical Center (UPMC) Pittsburgh, Pennsylvania | Abbey Sung - (sunga3@upmc.edu) |
| University of Rochester Medical Center Rochester, New York | Lori Caufield - (lori_caufield@urmc.rochester.edu) |
| University of Utah Hospital Salt Lake City, Utah | Ashley Elmer - (ashley.elmer@hsc.utah.edu) |
| University of Virginia Medical Center Charlottesville, Virginia | Tevin Jefferson - (MFU3QX@uvahealth.org) |
| Virginia Commonwealth University Richmond, Virginia | Saige Dagenhart - (Saige.Dagenhart@vcuhealth.org) |
| Washington Hospital Center Washington D.C., District of Columbia | Hellina Birru - (hellina.t.birru@medstar.net) |
| Wellstar Kennestone Hospital Marietta, Georgia | Amuthanayaki Kanagaraj - (amuthanayaki.kanagaraj2@wellstar.org) |
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
ctrrecruit@vcu.edu
NCT07466316
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must be ≤ 50 years of age at the time of enrollment
* Patients with newly diagnosed soft tissue RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon FOXO1 fusion status, Stage, Intergroup Rhabdomyosarcoma Study (IRS) group, and age, as below. FOXO1 fusion status must be determined prior to enrollment. RMS types included under embryonal rhabdomyosarcoma (ERMS) include those which are reclassified in the 2020 World Health Organization (WHO) classification as ERMS (typical, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant). Classification of alveolar Rhabdomyosarcoma (ARMS) in the 2020 WHO Classification is the same as in the International Classification of Rhabdomyosarcoma (ICR) and includes classic and solid variants.
* FOXO1 fusion negative (FN)
* Stage 2/3, Group III
* Stage 4, Group IV, \< 10 years old
* FOXO1 fusion positive (FP)
* Stages 1-3, Groups I-III
* Disease/staging imaging studies, if applicable, must be obtained within 21 days prior to enrollment and start of protocol therapy (repeat if necessary)
* FOXO1 status results must be available to enroll. All patients will undergo institutional pathology review and institutional FOXO1 fusion determination regardless of histology prior to enrollment. FOXO1 status may confirmed by cytogenetic, fluorescence in situ hybridization (FISH), or next generation sequencing techniques. FOXO1 fusion results should be SUBMITTED as an upload to RAVE at study enrollment because this information is required for randomization.
Please note the following:
* Institutional PAX3 versus (vs.) PAX7 determination is not required but should be submitted if available. Institutional FOXO1 testing may be performed at a contract or commercial lab as long as reports can be submitted and uploaded to RAVE. Additional molecular pathology reports, including the MCI report, are not required but should be submitted if available.
* Patients who are \< 10 years old with distant metastatic disease (Stage 4) who have institutional molecular testing indicating fusion negative (FN) RMS but are later found to have fusion positive (FP) RMS by MCI or other testing will be considered to have metastatic FP disease and will go off study
* Appropriate lymph node sampling based on primary site of disease is required
* Patients must have a performance status of Lansky performance status score ≥ 50 for patients ≤ 16 years of age or Karnofsky performance status score ≥ 50 for patients \> 16 years of age
* Peripheral absolute neutrophil count (ANC) ≥ 750/μL (All laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory studies must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment. Laboratory tests need not be repeated if therapy starts within seven (7) days of their most recent prior assessment. If the result of a laboratory study that is repeated at any time post-enrollment and prior to the start of protocol therapy is outside the limits for eligibility, then the evaluation must be rechecked within 48 hours prior to initiating protocol therapy. The results of the recheck must be within the limits for eligibility to proceed. If the result of the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.)
* Platelet count ≥ 75,000/μL (All laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory studies must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment. Laboratory tests need not be repeated if therapy starts within seven (7) days of their most recent prior assessment. If the result of a laboratory study that is repeated at any time post-enrollment and prior to the start of protocol therapy is outside the limits for eligibility, then the evaluation must be rechecked within 48 hours prior to initiating protocol therapy. The results of the recheck must be within the limits for eligibility to proceed. If the result of the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.)
* For pediatric patients \< 18 years of age:
* A serum creatinine based on age/sex as follows:
* 1 month to \< 6 months: Maximum serum creatinine 0.4 mg/dL (male), 0.4 mg/dL (female)
* 6 months to \< 1 year: Maximum serum creatinine 0.5 mg/dL (male), 0.5 mg/dL (female)
* 1 to \< 2 years: Maximum serum creatinine 0.6 mg/dL (male), 0.6 mg/dL (female)
* 2 to \< 6 years: Maximum serum creatinine 0.8 mg/dL (male), 0.8 mg/dL (female)
* 6 to \< 10 years: Maximum serum creatinine 1 mg/dL (male), 1 mg/dL (female)
* 10 to \< 13 years: Maximum serum creatinine 1.2 mg/dL (male), 1.2 mg/dL (female)
* 13 to \< 16 years: Maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
* ≥ 16 years: Maximum serum creatinine 1.7 mg/dL (male),1.4 mg/dL (female)
* OR a 24-hour urine Creatinine clearance ≥ 50 mL/min/1.73 m\^2
* OR a glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard).
* Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility.
* Patients with an elevated serum creatinine due to obstructive hydronephrosis secondary to tumor are still eligible. However, patients with urinary tract obstruction by tumor must have unimpeded urinary flow established via diversion (ie, percutaneous nephrostomies or ureteric stents) of the urinary tract.
For adult patients (aged 18 years or older):
* Creatinine clearance ≥ 50 mL/min, as estimated by the Cockcroft and Gault formula or as a 24-hour urine collection. Estimated creatinine clearance is based on actual body weight.
(All laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory studies must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment. Laboratory tests need not be repeated if therapy starts within seven (7) days of their most recent prior assessment. If the result of a laboratory study that is repeated at any time post-enrollment and prior to the start of protocol therapy is outside the limits for eligibility, then the evaluation must be rechecked within 48 hours prior to initiating protocol therapy. The results of the recheck must be within the limits for eligibility to proceed. If the result of the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.)
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age (All laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory studies must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment. Laboratory tests need not be repeated if therapy starts within seven (7) days of their most recent prior assessment. If the result of a laboratory study that is repeated at any time post-enrollment and prior to the start of protocol therapy is outside the limits for eligibility, then the evaluation must be rechecked within 48 hours prior to initiating protocol therapy. The results of the recheck must be within the limits for eligibility to proceed. If the result of the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.)
* If there is evidence of biliary obstruction by tumor, then total bilirubin must be \< 3 x ULN for age
* Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 135 U/L (All laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory studies must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment. Laboratory tests need not be repeated if therapy starts within seven (7) days of their most recent prior assessment. If the result of a laboratory study that is repeated at any time post-enrollment and prior to the start of protocol therapy is outside the limits for eligibility, then the evaluation must be rechecked within 48 hours prior to initiating protocol therapy. The results of the recheck must be within the limits for eligibility to proceed. If the result of the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.)
* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L.
* Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Exclusion Criteria:
* Patients with evidence of uncontrolled infection are not eligible
* Previous or concurrent cancer(s) that is/was being treated with chemotherapy and/or radiation.
* Note: Surgical resection alone of previous or concurrent cancer(s) is allowed
* Patients with central nervous system involvement of RMS as defined below:
* Malignant cells detected in cerebrospinal fluid
* Intra-parenchymal brain metastases separate and distinct from primary tumor (i.e., direct extension from parameningeal primary tumors is allowed)
* Diffuse leptomeningeal disease
* Patients with known Charcot-Marie-Tooth disease
* Patients who have received any chemotherapy (excluding steroids) and/or radiation therapy for RMS prior to enrollment. Note: the following exception:
* Patients requiring emergency radiation therapy for life-threatening complications of tumor burden due to RMS. These patients are eligible, provided they are consented to ARST2531 prior to administration of radiation.
* Note: Patients who have received or are receiving chemotherapy or radiation for non-malignant conditions (eg, autoimmune diseases) are eligible. Patients must discontinue chemotherapy for non-malignant conditions prior to starting protocol therapy
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
* Lactating females who plan to breastfeed their infants
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, PROCEDURE: Bone Scan, PROCEDURE: Computed Tomography, DRUG: Cyclophosphamide, BIOLOGICAL: Dactinomycin, DRUG: Irinotecan Hydrochloride, PROCEDURE: Lumbar Puncture, PROCEDURE: Lymph Node Biopsy, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, RADIATION: Radiation Therapy, PROCEDURE: Resection, OTHER: Survey Administration, DRUG: Vincristine Sulfate, DRUG: Vinorelbine Tartrate
Rhabdomyosarcoma
I'm interested
Share via email
Show 138 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Albany Medical Center Albany, New York | |
| Alfred I duPont Hospital for Children Wilmington, Delaware | Site Public Contact - (Allison.bruce@nemours.org) |
| Arkansas Children's Hospital Little Rock, Arkansas | |
| Arnold Palmer Hospital for Children Orlando, Florida | Site Public Contact - (Jennifer.spinelli@orlandohealth.com) |
| Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana | Site Public Contact - (research@stvincent.org) |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas | Site Public Contact - (burton@bcm.edu) |
| Beacon Kalamazoo Kalamazoo, Michigan | |
| Blank Children's Hospital Des Moines, Iowa | Site Public Contact - (samantha.mallory@unitypoint.org) |
| Bronson Battle Creek Battle Creek, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Bronson Methodist Hospital Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL) Québec, | Site Public Contact - (rechclinique@crchudequebec.ulaval.ca) |
| Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan | |
| CancerCare Manitoba Winnipeg, Manitoba | Site Public Contact - (ctu_web@cancercare.mb.ca) |
| Cardinal Glennon Children's Medical Center St Louis, Missouri | |
| Carle BroMenn Medical Center Normal, Illinois | Site Public Contact - (Research@Carle.com) |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Cancer Institute Normal Normal, Illinois | Site Public Contact - (Research@Carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina | |
| Cedars-Sinai Medical Center Los Angeles, California | Site Public Contact - (Cancer.trial.info@cshs.org) |
| Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec | Site Public Contact - (yvan.samson@umontreal.ca) |
| Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia | Site Public Contact - (Olivia.Floyd@choa.org) |
| Children's Hospital Colorado Aurora, Colorado | Site Public Contact - (josh.b.gordon@nsmtp.kp.org) |
| Children's Hospital Medical Center Of Akron Akron, Ohio | |
| Children's Hospital New Orleans New Orleans, Louisiana | |
| Children's Hospital and Medical Center of Omaha Omaha, Nebraska | |
| Children's Hospital of Alabama Birmingham, Alabama | Site Public Contact - (oncologyresearch@peds.uab.edu) |
| Children's Hospital of Orange County Orange, California | Site Public Contact - (oncresearch@choc.org) |
| Children's Hospital of Philadelphia Philadelphia, Pennsylvania | Site Public Contact - (CancerTrials@email.chop.edu) |
| Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania | Site Public Contact - (jean.tersak@chp.edu) |
| Children's Hospital of San Antonio San Antonio, Texas | Site Public Contact - (bridget.medina@christushealth.org) |
| Children's Hospital of Wisconsin Milwaukee, Wisconsin | Site Public Contact - (MACCCTO@mcw.edu) |
| Children's Hospital of the King's Daughters Norfolk, Virginia | Site Public Contact - (CCBDCresearch@chkd.org) |
| Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota | Site Public Contact - (pauline.mitby@childrensmn.org) |
| Children's Mercy Hospitals and Clinics Kansas City, Missouri | Site Public Contact - (COGResearchGroup@cmh.edu) |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@cchmc.org) |
| City of Hope Comprehensive Cancer Center Duarte, California | Site Public Contact - (becomingapatient@coh.org) |
| Connecticut Children's Medical Center Hartford, Connecticut | |
| Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan | |
| Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Reed City Hospital Reed City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Covenant Children's Hospital Lubbock, Texas | |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Dayton Children's Hospital Dayton, Ohio | |
| Dell Children's Medical Center of Central Texas Austin, Texas | Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org) |
| Driscoll Children's Hospital Corpus Christi, Texas | Site Public Contact - (Crystal.DeLosSantos@dchstx.org) |
| East Tennessee Childrens Hospital Knoxville, Tennessee | |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (cancerresearch@geisinger.edu) |
| Golisano Children's Hospital of Southwest Florida Fort Myers, Florida | Site Public Contact - (molly.arnstrom@leehealth.org) |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Inova Fairfax Hospital Falls Church, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Johns Hopkins All Children's Hospital St. Petersburg, Florida | Site Public Contact - (Ashley.Repp@jhmi.edu) |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Legacy Emanuel Children's Hospital Portland, Oregon | |
| Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Loma Linda University Medical Center Loma Linda, California | |
| Lurie Children's Hospital-Chicago Chicago, Illinois | |
| Madigan Army Medical Center Tacoma, Washington | Site Public Contact - (melissa.a.forouhar.mil@health.mil) |
| Maimonides Medical Center Brooklyn, New York | |
| Maine Children's Cancer Program Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| MaineHealth Cancer Care Center of York County Sanford, Maine | |
| MaineHealth Coastal Cancer Treatment Center Bath, Maine | |
| MaineHealth Maine Medical Center - Portland Portland, Maine | |
| MaineHealth Maine Medical Center- Scarborough Scarborough, Maine | |
| Mary Bridge Children's Hospital and Health Center Tacoma, Washington | Site Public Contact - (research@multicare.org) |
| Massachusetts General Hospital Cancer Center Boston, Massachusetts | |
| Mattel Children's Hospital UCLA Los Angeles, California | |
| Mayo Clinic in Rochester Rochester, Minnesota | |
| Memorial Health University Medical Center Savannah, Georgia | Site Public Contact - (Lorraine.OHara@hcahealthcare.com) |
| Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida | Site Public Contact - (OHR@mhs.net) |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Methodist Children's Hospital of South Texas San Antonio, Texas | Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com) |
| Miller Children's and Women's Hospital Long Beach Long Beach, California | |
| Mission Hospital Asheville, North Carolina | Site Public Contact - (NCDV.ResearchRegulatory@HCAHealthcare.com) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Morristown Medical Center Morristown, New Jersey | |
| Munson Medical Center Traverse City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Nemours Children's Clinic - Pensacola Pensacola, Florida | Site Public Contact - (helpdesk@childrensoncologygroup.org) |
| Nemours Children's Clinic-Jacksonville Jacksonville, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| Nemours Children's Hospital Orlando, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| New York Medical College Valhalla, New York | |
| Newark Beth Israel Medical Center Newark, New Jersey | Site Public Contact - (Christine.Kosmides@rwjbh.org) |
| Norton Children's Hospital Louisville, Kentucky | Site Public Contact - (CancerResource@nortonhealthcare.org) |
| Novant Health Presbyterian Medical Center Charlotte, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Oregon Health and Science University Portland, Oregon | Site Public Contact - (trials@ohsu.edu) |
| Primary Children's Hospital Salt Lake City, Utah | |
| ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington | Site Public Contact - (HopeBeginsHere@providence.org) |
| Rainbow Babies and Childrens Hospital Cleveland, Ohio | |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (Renown-CRD@renown.org) |
| Rhode Island Hospital Providence, Rhode Island | |
| Riley Hospital for Children Indianapolis, Indiana | |
| Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Denver, Colorado | Site Public Contact - (PSGResearchSharedMailbox@HCAHealthcare.com) |
| Roswell Park Cancer Institute Buffalo, New York | Site Public Contact - (askroswell@roswellpark.org) |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey | |
| Saint Christopher's Hospital for Children Philadelphia, Pennsylvania | |
| Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida | Site Public Contact - (jennifer.manns@baycare.org) |
| Saint Mary's Medical Center West Palm Beach, Florida | |
| Sanford Broadway Medical Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Seattle Children's Hospital Seattle, Washington | |
| Sinai Hospital of Baltimore Baltimore, Maryland | |
| State University of New York Upstate Medical University Syracuse, New York | |
| The Children's Hospital at TriStar Centennial Nashville, Tennessee | |
| Trinity Health Grand Rapids Hospital Grand Rapids, Michigan | |
| Trinity Health Muskegon Hospital Muskegon, Michigan | |
| UCSF Benioff Children's Hospital Oakland Oakland, California | Site Public Contact - (PedOncRschOAK@ucsf.edu) |
| UCSF Medical Center-Mission Bay San Francisco, California | Site Public Contact - (cancertrials@ucsf.edu) |
| UMC Cancer Center / UMC Health System Lubbock, Texas | |
| UMass Memorial Medical Center - University Campus Worcester, Massachusetts | Site Public Contact - (cancer.research@umassmed.edu) |
| UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina | Site Public Contact - (cancerclinicaltrials@med.unc.edu) |
| USA Health Strada Patient Care Center Mobile, Alabama | |
| UT MD Anderson Cancer Center Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| University of Alberta Hospital Edmonton, Alberta | Site Public Contact - (pedsoncologyresearch@ahs.ca) |
| University of Illinois Chicago, Illinois | |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Michigan Health - West Wyoming, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota | |
| University of Mississippi Medical Center Jackson, Mississippi | |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of Rochester Rochester, New York | |
| University of Texas Health Science Center at San Antonio San Antonio, Texas | Site Public Contact - (phoresearchoffice@uthscsa.edu) |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Children's Hospital Madera, California | Site Public Contact - (Research@valleychildrens.org) |
| Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Wesley Medical Center Wichita, Kansas | Site Public Contact - (WesleyResearch@wesleymc.com) |
| West Michigan Cancer Center Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease (STARSCAPE-1)
Trial Transparency email recommended (Toll free for US & Canada) - Contact-US@sanofi.com
NCT07184931
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to \<18 years of age who meet the definition of Tanner Stage 5 for development
* Confirmed diagnosis of moderately to severely active Crohn's Disease (CD) for at least 3 months prior to baseline
* Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies (ATs)
Exclusion Criteria:
* Participants with Ulcerative Colitis (UC) or indeterminate colitis
* Participants with two entire missing segments of the: terminal ileum, right colon transverse colon, sigmoid and left colon, and rectum
* Prior or current high-grade gastrointestinal (GI) dysplasia
* Participants on treatment with but not on stable doses of conventional therapy prior to baseline
* Participants receiving prohibited medications or therapies
* Participants with previous exposure to anti-TL1A investigational therapy
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial. DRUG: Duvakitug, DRUG: Placebo
Crohn's Disease
I'm interested
Share via email
Show 481 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AdventHealth Orlando-Site Number: 8400070 Orlando, Florida | |
| Alliance Research Institute-Site Number: 8400008 Canoga Park, California | |
| Allied Health Clinical Research Organization, LLC - Freehold-Site Number: 8400014 Freehold, New Jersey | |
| Allied Health Clinical Research Organization, LLC - Jackson-Site Number:8400007 Jackson, Mississippi | |
| Amicis Research Center - Valencia-Site Number: 8400064 Valencia, California | |
| Atlanta Gastroenterology Associates-Site Number: 8400109 Atlanta, Georgia | |
| Atlanta Gastroenterology Specialists-Site Number: 8400149 Suwanee, Georgia | |
| Atlantic Health System, Morristown Medical Center-Site Number: 8400137 Morristown, New Jersey | |
| BVL Clinical Research-Site Number: 8400005 Liberty, Missouri | |
| Baylor College of Medicine-Site Number: 8400140 Houston, Texas | |
| Biocentric Health Research Center-Site Number: 8400089 Columbia, South Carolina | |
| Bioresearch Partner-Kendale Lakes-Site Number: 8400053 Miami, Florida | |
| Blue Ridge Medical Research-Site Number: 8400020 Lynchburg, Virginia | |
| Blue River Clinical Research-Site Number: 8400160 Kansas City, Missouri | |
| Care Access - New Iberia-Site Number: 8400031 New Iberia, Louisiana | |
| Central Sooner Research-Site Number: 8400094 Norman, Oklahoma | |
| ClinTrial Research, LLC-Site Number: 8400043 Raleigh, North Carolina | |
| Clinical Applications Laboratories Inc-Site Number: 8400056 San Diego, California | |
| Clinical Research Partners-Site Number: 8400080 Richmond, Virginia | |
| Clinical Research of Osceola-Site Number: 8400013 Kissimmee, Florida | |
| Clinical Trials Management Services-Site Number: 8400047 Thousand Oaks, California | |
| Columbia University Medical Center-Site Number: 8400138 New York, New York | |
| Columbus Clinical Services LLc-Site Number: 8400038 Miami, Florida | |
| Correa Research Center-Site Number: 8400010 Miami, Florida | |
| Cross Creek Medical Clinic-Site Number: 8400057 Fayetteville, North Carolina | |
| DSI Research - Springboro-Site Number: 8400105 Springboro, Ohio | |
| DSI Research Northridge - Dayton-Site Number: 8400115 Dayton, Ohio | |
| Dayton Gastroenterology, Inc - Dayton-Site Number: 8400166 Dayton, Ohio | |
| Del Sol Research Management, LLC-Site Number: 8400012 Tucson, Arizona | |
| Delta Research Partners-Site Number: 8400087 Monroe, Louisiana | |
| Digestive Health Research Center-Site Number: 8400096 Waterloo, Iowa | |
| Duke University Medical Center-Site Number: 8400093 Durham, North Carolina | |
| EBGS Clinical Research Center, LLC-Site Number: 8400037 Snellville, Georgia | |
| Elite Clinical Studies, LLC-Site Number: 8400162 Phoenix, Arizona | |
| Erick H. Alayo Medical Corporation-Site Number: 8400159 Chula Vista, California | |
| Froedtert Hospital and the Medical College of Wisconsin-Site Number: 8400081 Milwaukee, Wisconsin | |
| GI Alliance - Baton Rouge-Site Number: 8400129 Baton Rouge, Louisiana | |
| GI Alliance - Bellevue-Site Number: 8400143 Bellevue, Washington | |
| GI Alliance - Glenview-Site Number: 8400068 Glenview, Illinois | |
| GI Alliance - Gurnee-Site Number: 8400049 Gurnee, Illinois | |
| GI Alliance - Lubbock-Site Number: 8400092 Lubbock, Texas | |
| GI Alliance - Metairie-Site Number: 8400124 Metairie, Louisiana | |
| GMC Clinical Research, LLC-Site Number: 8400113 Folsom, California | |
| Gastro Health Holdco, LLC-Site Number: 8400024 Maitland, Florida | |
| Gastro One - Cordova-Site Number: 8400158 Cordova, Tennessee | |
| GastroIntestinal Bioscience - Los Angeles-Site Number: 8400019 Los Angeles, California | |
| Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139 Canton, Ohio | |
| Gastroenterology Associates of Western Michigan-Site Number: 8400060 Wyoming, Michigan | |
| Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100 New Albany, Indiana | |
| Gastroenterology Research of San Antonio LLC-Site Number: 8400054 San Antonio, Texas | |
| Gastroenterology and Liver Institute - Escondido-Site Number: 8400146 Escondido, California | |
| Gastroenterology of the Rockies - Denver-Site Number: 8400122 Denver, Colorado | |
| Gateway Gastroenterology-Site Number: 8400097 St Louis, Missouri | |
| Grand Teton Research Group, PLLC-Site Number: 8400127 Idaho Falls, Idaho | |
| Heartland Medical Research, Inc.-Site Number: 8400134 Clive, Iowa | |
| Henry Ford Medical Center - Columbus-Site Number: 8400118 Novi, Michigan | |
| Innovare Research Group-Site number: 8400067 Lake Jackson, Texas | |
| Inquest Clinical Research-Site Number: 8400144 Baytown, Texas | |
| Investigational Site Number : 0320001 Buenos Aires, City of Buenos Aires | |
| Investigational Site Number : 0320002 La Plata, Buenos Aires | |
| Investigational Site Number : 0320003 Buenos Aires, | |
| Investigational Site Number : 0320004 Córdoba, | |
| Investigational Site Number : 0320005 Buenos Aires, | |
| Investigational Site Number : 0320006 Rosario, Santa Fe Province | |
| Investigational Site Number : 0320007 Rosario, Santa Fe Province | |
| Investigational Site Number : 0360001 South Brisbane, | |
| Investigational Site Number : 0360002 Southport, | |
| Investigational Site Number : 0360003 Clayton, | |
| Investigational Site Number : 0360004 Liverpool, | |
| Investigational Site Number : 0360005 Birtinya, | |
| Investigational Site Number : 0360006 Nedlands, | |
| Investigational Site Number : 0360007 Wollongong, | |
| Investigational Site Number : 0400001 Vienna, | |
| Investigational Site Number : 0400002 Salzburg, | |
| Investigational Site Number : 0400003 Krems, Lower Austria | |
| Investigational Site Number : 0400004 Graz, Styria | |
| Investigational Site Number : 0400005 Linz, Upper Austria | |
| Investigational Site Number : 0400006 Sankt Veit an der Glan, Carinthia | |
| Investigational Site Number : 0400007 Vienna, | |
| Investigational Site Number : 0400008 Vienna, | |
| Investigational Site Number : 0560001 Genk, | |
| Investigational Site Number : 0560002 Sint-Niklaas, | |
| Investigational Site Number : 0560003 Yvoir, | |
| Investigational Site Number : 0560004 Liège, | |
| Investigational Site Number : 0760001 Goiânia, | |
| Investigational Site Number : 0760006 São José do Rio Preto, Sao Jose Do Rio Preto, Sao Paulo | |
| Investigational Site Number : 0760007 Porto Alegre, | |
| Investigational Site Number : 0760008 Aracaju, | |
| Investigational Site Number : 0760009 Porto Alegre, Rio Grande do Sul | |
| Investigational Site Number : 0760010 Brasília, | |
| Investigational Site Number : 0760011 Teresina, | |
| Investigational Site Number : 0760012 Campinas, São Paulo | |
| Investigational Site Number : 0760013 Salvador, | |
| Investigational Site Number : 0760014 São Paulo, | |
| Investigational Site Number : 1000001 Sofia, | |
| Investigational Site Number : 1000002 Sofia, | |
| Investigational Site Number : 1000003 Gorna Oryahovitsa, Oblast Veliko Tirnovo | |
| Investigational Site Number : 1000004 Sofia, | |
| Investigational Site Number : 1000005 Sofia, | |
| Investigational Site Number : 1000006 Sofia, | |
| Investigational Site Number : 1000007 Rusa, | |
| Investigational Site Number : 1000008 Sofia, | |
| Investigational Site Number : 1240002 Montreal, | |
| Investigational Site Number : 1240003 Toronto, | |
| Investigational Site Number : 1240004 Edmonton, | |
| Investigational Site Number : 1240005 Greater Sudbury, | |
| Investigational Site Number : 1240006 New Westminster, | |
| Investigational Site Number : 1240007 Montreal, | |
| Investigational Site Number : 1240009 Hamilton, | |
| Investigational Site Number : 1240010 Oakville, Ontario | |
| Investigational Site Number : 1240011 London, | |
| Investigational Site Number : 1240013 London, | |
| Investigational Site Number : 1240014 Brampton, | |
| Investigational Site Number : 1520001 Viña del Mar, | |
| Investigational Site Number : 1520002 Santiago, | |
| Investigational Site Number : 1520003 Santiago, | |
| Investigational Site Number : 1520004 Santiago, | |
| Investigational Site Number : 1560001 Chengdu, | |
| Investigational Site Number : 1560002 Guangzhou, Guangdong | |
| Investigational Site Number : 1560003 Wuhan, Hubei | |
| Investigational Site Number : 1560004 Nanjing, Jiangsu | |
| Investigational Site Number : 1560005 Hangzhou, | |
| Investigational Site Number : 1560006 Xiamen, Fujian | |
| Investigational Site Number : 1560007 Wenzhou, | |
| Investigational Site Number : 1560008 Jinan, | |
| Investigational Site Number : 1560009 Guangzhou, | |
| Investigational Site Number : 1560010 Wuhan, Hubei | |
| Investigational Site Number : 1560011 Changzhou, | |
| Investigational Site Number : 1560013 Hangzhou, Zhejiang | |
| Investigational Site Number : 1560016 Beijing, | |
| Investigational Site Number : 1560017 Changshu, | |
| Investigational Site Number : 1560018 Wuxi, Jiangsu | |
| Investigational Site Number : 1560019 Nanjing, | |
| Investigational Site Number : 1560020 Shanghai, | |
| Investigational Site Number : 1560022 Jingzhou, | |
| Investigational Site Number : 1560023 Nanjing, | |
| Investigational Site Number : 1560024 Nanjing, | |
| Investigational Site Number : 1560025 Nanjing, Jiangsu | |
| Investigational Site Number : 1560026 Huizhou, Guangdong | |
| Investigational Site Number : 1560027 Beijing, | |
| Investigational Site Number : 1560029 Taizhou, Zhejiang | |
| Investigational Site Number : 1560030 Mianyang, | |
| Investigational Site Number : 1560033 Wuhan, Hubei | |
| Investigational Site Number : 1560034 Guangzhou, Guangdong | |
| Investigational Site Number : 1560036 Fuzhou, | |
| Investigational Site Number : 1560037 Changsha, Hunan | |
| Investigational Site Number : 1560038 Beijing, | |
| Investigational Site Number : 1560039 Luzhou, | |
| Investigational Site Number : 1560040 Zhengzhou, | |
| Investigational Site Number : 1560042 Suzhou, | |
| Investigational Site Number : 1560043 Shenzhen, Guangdong | |
| Investigational Site Number : 1560049 Guangzhou, Guangdong | |
| Investigational Site Number : 1560050 Yangzhou, | |
| Investigational Site Number : 1560056 Jinhua, | |
| Investigational Site Number : 1560057 Qingdao, | |
| Investigational Site Number : 1560058 Shanghai, | |
| Investigational Site Number : 1560059 Qingyuan, | |
| Investigational Site Number : 1560060 Hefei, | |
| Investigational Site Number : 1560061 Chengdu, | |
| Investigational Site Number : 1580001 Taoyuan City, | |
| Investigational Site Number : 1580002 Taipei, | |
| Investigational Site Number : 1580003 Chiayi City, | |
| Investigational Site Number : 1580005 Changhua County, | |
| Investigational Site Number : 1580006 Kaohsiung City, | |
| Investigational Site Number : 1580007 Tainan, | |
| Investigational Site Number : 1580008 Tainan, | |
| Investigational Site Number : 1580009 New Taipei City, | |
| Investigational Site Number : 1580010 Kaohsiung City, | |
| Investigational Site Number : 1700001 Armenia, Quindío Department | |
| Investigational Site Number : 1700002 Medellín, Antioquia | |
| Investigational Site Number : 1700003 Barranquilla, Atlántico | |
| Investigational Site Number : 1700004 Floridablanca, Santander Department | |
| Investigational Site Number : 1700005 Medellín, Antioquia | |
| Investigational Site Number : 1700006 Medellín, Antioquia | |
| Investigational Site Number : 2030001 Brno, | |
| Investigational Site Number : 2030002 Slaný, | |
| Investigational Site Number : 2030003 Brno, | |
| Investigational Site Number : 2030006 Prague, | |
| Investigational Site Number : 2030008 Brno, | |
| Investigational Site Number : 2030011 Hradec Králové, | |
| Investigational Site Number : 2030013 Prague, | |
| Investigational Site Number : 2500001 Paris, | |
| Investigational Site Number : 2500002 Saint-Etienne, Cedex 2 | |
| Investigational Site Number : 2500003 Créteil, | |
| Investigational Site Number : 2500004 La Tronche, | |
| Investigational Site Number : 2500005 Nantes, | |
| Investigational Site Number : 2500006 Vandœuvre-lès-Nancy, | |
| Investigational Site Number : 2500007 Nantes, | |
| Investigational Site Number : 2500008 Besançon, | |
| Investigational Site Number : 2500009 Amiens, Cedex 1 | |
| Investigational Site Number : 2500010 Lille, | |
| Investigational Site Number : 2500011 Toulouse, | |
| Investigational Site Number : 2500012 Marseille, | |
| Investigational Site Number : 2500013 Nice, | |
| Investigational Site Number : 2680001 Tbilisi, | |
| Investigational Site Number : 2680002 Tbilisi, | |
| Investigational Site Number : 2680003 Tbilisi, | |
| Investigational Site Number : 2680004 Tbilisi, | |
| Investigational Site Number : 2680005 Tbilisi, | |
| Investigational Site Number : 2680006 Tbilisi, | |
| Investigational Site Number : 2680007 Kutaisi, | |
| Investigational Site Number : 2680008 Tbilisi, | |
| Investigational Site Number : 2680009 Tbilisi, | |
| Investigational Site Number : 2760001 Kiel, | |
| Investigational Site Number : 2760003 Berlin, | |
| Investigational Site Number : 2760004 Hamburg, | |
| Investigational Site Number : 2760005 Ulm, | |
| Investigational Site Number : 2760006 Berlin, | |
| Investigational Site Number : 2760007 Duisburg, | |
| Investigational Site Number : 2760008 Dresden, Saxony | |
| Investigational Site Number : 2760009 Tübingen, Baden-Wurttemberg | |
| Investigational Site Number : 2760010 Minden, | |
| Investigational Site Number : 2760013 Remscheid, North Rhine-Westphalia | |
| Investigational Site Number : 2760014 Ludwigshafen am Rhein, Rhineland-Palatinate | |
| Investigational Site Number : 2760015 Leipzig, | |
| Investigational Site Number : 2760016 Jerichow, Saxony-Anhalt | |
| Investigational Site Number : 2760017 Berlin, | |
| Investigational Site Number : 2760019 Dachau, | |
| Investigational Site Number : 2760020 Leipzig, Saxony | |
| Investigational Site Number : 2760021 Halle, Saxony-Anhalt | |
| Investigational Site Number : 2760023 Würzburg, Bavaria | |
| Investigational Site Number : 2760024 Erlangen, | |
| Investigational Site Number : 2760026 Herne, | |
| Investigational Site Number : 2760029 Lüneburg, | |
| Investigational Site Number : 3000001 Heraklion, Crete | |
| Investigational Site Number : 3000002 Athens, | |
| Investigational Site Number : 3000003 Larissa, Thessaly | |
| Investigational Site Number : 3480001 Veszprém, | |
| Investigational Site Number : 3480002 Budapest, | |
| Investigational Site Number : 3480003 Tatabánya, | |
| Investigational Site Number : 3480004 Budapest, | |
| Investigational Site Number : 3480005 Eger, | |
| Investigational Site Number : 3760001 Jerusalem, | |
| Investigational Site Number : 3760002 Tel Aviv, | |
| Investigational Site Number : 3760003 Beersheba, | |
| Investigational Site Number : 3760004 Afula, | |
| Investigational Site Number : 3760005 Nahariya, | |
| Investigational Site Number : 3760006 Ashkelon, | |
| Investigational Site Number : 3760007 Petah Tikva, | |
| Investigational Site Number : 3800002 Milan, | |
| Investigational Site Number : 3800003 Rozzano, | |
| Investigational Site Number : 3800005 Turin, | |
| Investigational Site Number : 3800006 San Donato Milanese, | |
| Investigational Site Number : 3800007 Legnano, | |
| Investigational Site Number : 3800009 Rome, | |
| Investigational Site Number : 3920001 Saga, | |
| Investigational Site Number : 3920002 Osaka, | |
| Investigational Site Number : 3920003 Sendai, | |
| Investigational Site Number : 3920004 Sendai, | |
| Investigational Site Number : 3920005 Asahikawa, | |
| Investigational Site Number : 3920006 Shinjuku, | |
| Investigational Site Number : 3920009 Tsu, | |
| Investigational Site Number : 3920012 Bunkyō City, | |
| Investigational Site Number : 3920013 Nishinomiya, | |
| Investigational Site Number : 3920014 Saga, | |
| Investigational Site Number : 3920015 Toyohashi, | |
| Investigational Site Number : 3920018 Kashiwa, | |
| Investigational Site Number : 3920019 Kobe, | |
| Investigational Site Number : 3920020 Shiwa-gun, | |
| Investigational Site Number : 3920022 Osaka, | |
| Investigational Site Number : 3920023 Sakura, | |
| Investigational Site Number : 3920024 Mitaka, | |
| Investigational Site Number : 3920025 Okayama, | |
| Investigational Site Number : 3920026 Nagoya, | |
| Investigational Site Number : 3920027 Fukuoka, | |
| Investigational Site Number : 3920028 Isesaki, | |
| Investigational Site Number : 3920029 Sapporo, | |
| Investigational Site Number : 3920030 Kamakura, | |
| Investigational Site Number : 3920031 Hachiōji, | |
| Investigational Site Number : 3920032 Toyama, | |
| Investigational Site Number : 3920033 Kōriyama, | |
| Investigational Site Number : 3920034 Shinjuku, | |
| Investigational Site Number : 3920035 Yokohama, | |
| Investigational Site Number : 3920036 Kumamoto, | |
| Investigational Site Number : 3920037 Toyama, | |
| Investigational Site Number : 3920039 Chikushino-shi, | |
| Investigational Site Number : 3920042 Sapporo, | |
| Investigational Site Number : 3920045 Fukuoka, | |
| Investigational Site Number : 3920046 Shizuoka, Hamamatsu | |
| Investigational Site Number : 3920047 Shimotsuga-gun, | |
| Investigational Site Number : 3920048 Sendai, | |
| Investigational Site Number : 3920049 Kagoshima, | |
| Investigational Site Number : 3920050 Osaka, | |
| Investigational Site Number : 3920052 Maebashi, | |
| Investigational Site Number : 3920054 Kitakyushu, | |
| Investigational Site Number : 3920057 Nagoya, | |
| Investigational Site Number : 3920058 Minato, | |
| Investigational Site Number : 3920059 Bunkyō City, | |
| Investigational Site Number : 3920060 Kobe, | |
| Investigational Site Number : 3920061 Kurume, | |
| Investigational Site Number : 3920062 Nagakute, | |
| Investigational Site Number : 3920063 Fukuoka, | |
| Investigational Site Number : 3920064 Sagamihara, | |
| Investigational Site Number : 3920065 Isehara, | |
| Investigational Site Number : 4100001 Seoul, | |
| Investigational Site Number : 4100002 Seoul, | |
| Investigational Site Number : 4100003 Daejeon, | |
| Investigational Site Number : 4100004 Daegu, | |
| Investigational Site Number : 4100005 Suwon, | |
| Investigational Site Number : 4100006 Seoul, | |
| Investigational Site Number : 4100007 Gwangju, | |
| Investigational Site Number : 4100008 Busan, | |
| Investigational Site Number : 4100009 Busan, | |
| Investigational Site Number : 4100010 Ansan-si, | |
| Investigational Site Number : 4400001 Kaunas, | |
| Investigational Site Number : 4400002 Panevezys, | |
| Investigational Site Number : 4840001 Jalisco, | |
| Investigational Site Number : 4840004 Veracruz, | |
| Investigational Site Number : 4840006 Monterrey, Nuevo León | |
| Investigational Site Number : 4980001 Chisinau, | |
| Investigational Site Number : 4980002 Chisinau, | |
| Investigational Site Number : 4980003 Chisinau, | |
| Investigational Site Number : 4980004 Chisinau, | |
| Investigational Site Number : 5280001 Nijmegen, | |
| Investigational Site Number : 5280002 Amsterdam, | |
| Investigational Site Number : 5280003 Tilburg, | |
| Investigational Site Number : 5540001 Christchurch, | |
| Investigational Site Number : 5540002 Tauranga, | |
| Investigational Site Number : 5540003 Lower Hutt, | |
| Investigational Site Number : 5540004 Auckland, | |
| Investigational Site Number : 5540005 Wellington, | |
| Investigational Site Number : 5780001 Lorenskog, | |
| Investigational Site Number : 5780002 Tromsø, | |
| Investigational Site Number : 6160001 Poznan, | |
| Investigational Site Number : 6160002 Szczecin, | |
| Investigational Site Number : 6160003 Warsaw, | |
| Investigational Site Number : 6160004 Sopot, | |
| Investigational Site Number : 6160005 Warsaw, | |
| Investigational Site Number : 6160006 Warsaw, | |
| Investigational Site Number : 6160007 Staszów, | |
| Investigational Site Number : 6160008 Warsaw, | |
| Investigational Site Number : 6160009 Warsaw, | |
| Investigational Site Number : 6160010 Opole, | |
| Investigational Site Number : 6160011 Lodz, | |
| Investigational Site Number : 6160012 Wadowice, | |
| Investigational Site Number : 6160013 Elblag, | |
| Investigational Site Number : 6160014 Katowice, | |
| Investigational Site Number : 6160015 Tychy, | |
| Investigational Site Number : 6160016 Lodz, | |
| Investigational Site Number : 6160017 Wroclaw, | |
| Investigational Site Number : 6160018 Poznan, | |
| Investigational Site Number : 6160019 Bydgoszcz, | |
| Investigational Site Number : 6160020 Szczecin, | |
| Investigational Site Number : 6160022 Krakow, | |
| Investigational Site Number : 6160023 Torun, | |
| Investigational Site Number : 6160025 Rzeszów, | |
| Investigational Site Number : 6160026 Bydgoszcz, | |
| Investigational Site Number : 6160027 Nowy Targ, | |
| Investigational Site Number : 6160028 Wrocklaw, | |
| Investigational Site Number : 6160029 Siedlce, | |
| Investigational Site Number : 6160030 Kłodzko, | |
| Investigational Site Number : 6160031 Warsaw, | |
| Investigational Site Number : 6160032 Olsztyn, | |
| Investigational Site Number : 6160034 Lublin, | |
| Investigational Site Number : 6160035 Katowice, | |
| Investigational Site Number : 6880001 Belgrade, | |
| Investigational Site Number : 6880002 Belgrade, | |
| Investigational Site Number : 6880003 Belgrade, | |
| Investigational Site Number : 6880004 Niš, | |
| Investigational Site Number : 6880006 Belgrade, | |
| Investigational Site Number : 6880007 Belgrade, | |
| Investigational Site Number : 7030001 Bratislava, | |
| Investigational Site Number : 7030002 Prešov, | |
| Investigational Site Number : 7030003 Košice, | |
| Investigational Site Number : 7030004 Prešov, | |
| Investigational Site Number : 7100001 Kempton Park, | |
| Investigational Site Number : 7100002 Cape Town, | |
| Investigational Site Number : 7100003 East London, | |
| Investigational Site Number : 7100004 Durban, | |
| Investigational Site Number : 7100005 Claremont, | |
| Investigational Site Number : 7100006 KwaZulu-Natal, | |
| Investigational Site Number : 7240002 Huelva, | |
| Investigational Site Number : 7240003 Santiago de Compostela, | |
| Investigational Site Number : 7240004 Madrid, | |
| Investigational Site Number : 7240005 Gijón, | |
| Investigational Site Number : 7240006 Ourense, Galicia | |
| Investigational Site Number : 7560001 Bern, | |
| Investigational Site Number : 7560002 Basel, | |
| Investigational Site Number : 7920002 Mersin, | |
| Investigational Site Number : 7920003 Ankara, | |
| Investigational Site Number : 8040001 Kyiv, | |
| Investigational Site Number : 8040002 Kyiv, | |
| Investigational Site Number : 8040003 Chernivtsi, | |
| Investigational Site Number : 8040004 Lviv, | |
| Investigational Site Number : 8040005 Lviv, | |
| Investigational Site Number : 8040006 Uzhhorod, | |
| Investigational Site Number : 8040008 Vinnytsia, | |
| Investigational Site Number : 8040009 Vinnytsia, | |
| Investigational Site Number : 8040010 Vinnytsia, | |
| Investigational Site Number : 8040011 Lviv, | |
| Investigational Site Number : 8040013 Kyiv, | |
| Investigational Site Number : 8260001 London, | |
| Investigational Site Number : 8260003 Rochdale, | |
| Investigational Site Number : 8260004 Norwich, | |
| Investigational Site Number : 8260005 Cambridge, | |
| Investigational Site Number : 8260007 London, | |
| Investigational Site Number : 8260008 Cottingham, Hull | |
| Investigational Site Number: 0760002 Barretos, São Paulo | |
| Investigational Site Number: 0760003 Caxias do Sul, Rio Grande do Sul | |
| Investigational Site Number: 0760005 Juiz de Fora, Minas Gerais | |
| Johns Hopkins University Gastroenterology and Hepatology-Site Number: 8400116 Columbia, South Carolina | |
| Las Vegas Clinical Trials-Site Number: 8400079 Las Vegas, Nevada | |
| Los Angeles General Medical Center-Site Number: 8400016 Los Angeles, California | |
| M3 Wake Research - Atlanta-Site Number: 8400028 Sandy Springs, Georgia | |
| Manhattan Clinical Research, LLC-Site Number: 8400069 New York, New York | |
| Mayo Clinic - Jacksonville-Site Number: 8400102 Jacksonville, Florida | |
| MedTraits NY-Site Number: 8400045 Maspeth, New York | |
| Medical Associates Research Group-Site Number:8400063 San Diego, California | |
| Medical Professional Clinical Research Center-Site Number: 8400119 Miami, Florida | |
| Mercy Medical Center, Baltimore-Site Number: 8400117 Baltimore, Maryland | |
| Mid-Atlantic GI Research, LLC-Site Number: 8400106 Laurel, Maryland | |
| Midwest Digestive Health and Nutrition-Site Number: 8400136 Des Plaines, Illinois | |
| Monroe Biomedical Research-Site Number: 8400046 Monroe, North Carolina | |
| Montefiore Medical Center - Bronx-Site Number: 8400142 The Bronx, New York | |
| NMC Research LLC-Site Number: 8400033 Tampa, Florida | |
| NYU Langone Health-Site Number: 8400091 New York, New York | |
| New York Gastroenterology Associates-Site Number: 8400009 New York, New York | |
| North Shore Gastroenterology Research-Site Number: 8400130 Westlake, Ohio | |
| Novum Research, LLC-Site Number: 8400003 Clermont, Florida | |
| OSU Wexner Medical Center-Site Number: 8400077 Columbus, Ohio | |
| Ohio Gastroenterology Group Inc.-8400006 Columbus, Ohio | |
| Om Research, LLC - Lancaster-Site Number: 8400148 Lancaster, California | |
| Om Research, LLC - Oxnard-Site Number: 8400150 Oxnard, California | |
| Om Research, LLC - Victorville-Site Number: 8400022 Victorville, California | |
| OnSite Clinical Solutions-Site Number: 8400051 Charlotte, North Carolina | |
| One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061 Scottsdale, Arizona | |
| One of a Kind Clinical Research Center TX, LLC-Site Number; 8400125 Kingwood, Texas | |
| Onyx Clinical Research - Site Number:8400021 Peoria, Arizona | |
| Oregon Health & Science University-Site Number: 8400131 Portland, Oregon | |
| Orlando Health, Inc.-Site Number: 8400084 Orlando, Florida | |
| Paradisus Med Research-Site Number: 8400036 Miami, Florida | |
| Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039 Colorado Springs, Colorado | |
| Penn State Milton S. Hershey Medical Center-Site Number: 8400066 Hershey, Pennsylvania | |
| Plains Clinical Research Center-Site Number: 8400078 Fargo, North Dakota | |
| Precision Clinical Research - Sunrise-Site Number: 8400059 Sunrise, Florida | |
| Preferred Research Partners-Site Number: 8400018 Little Rock, Arkansas | |
| Premier Health Research, LLC-Site Number: 8400114 Sparta, New Jersey | |
| Prospective Research Innovations Inc.-Site Number: 8400017 Rancho Cucamonga, California | |
| Puerto Rico Health and Wellness Institute-Site Number: 8400104 Dorado, | |
| Regis Clinical Research, LLC-Site Number: 8400041 Miami, Florida | |
| Rush University Medical Center-Site Number: 8400015 Chicago, Illinois | |
| SMS Clinical Research-Site Number: 8400035 Mesquite, Texas | |
| SUNY Upstate Medical University-Site Number: 8400156 Syracuse, New York | |
| Sanmora Bespoke Clinical Research Solutions LLC-Site Number: 8400123 East Orange, New Jersey | |
| Sarkis Clinical Trials - Gainesville-Site Number: 8400048 Gainesville, Florida | |
| Scottsdale Clinical Trials-Site Number: 8400145 Scottsdale, Arizona | |
| Southern California GI & Liver Centers-Site Number: 8400062 Coronado, California | |
| Sylvester Comprehensive Cancer Center - A University of Miami Hospital and Clinics Facility - Miami-Site Number: 8400111 Miami, Florida | |
| TLC Clinical Research Inc.-Site Number: 8400030 Los Angeles, California | |
| Tandem Clinical Research - Marrero-Site Number: 8400002 Marrero, Louisiana | |
| Tandem Intermediate, LLC - Houma-Site Number: 8400034 Houma, Louisiana | |
| Tandem-Allied Clinical Research - Somers Point-Site Number: 8400050 Somers Point, New Jersey | |
| Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128 Mandeville, Louisiana | |
| Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake - Corporate Office-Site Number: 8400101 Southlake, Texas | |
| Texas Gastro Consultants-Site Number: 8400029 Tomball, Texas | |
| The Allegheny Health Network (AHN) Center for Digestive Health-Site Number: 8400107 Pittsburgh, Pennsylvania | |
| The University of Texas Southwestern Medical Center-Site Number: 8400098 Dallas, Texas | |
| The Vancouver Clinic Inc. P.S.-Site Number: 8400090 Vancouver, Washington | |
| Tri-Cities Gastroenterology-Site Number: 8400076 Kingsport, Tennessee | |
| Tropical Clinical Trials-Site Number: 8400082 Palmetto Bay, Florida | |
| Tufts Medical Center-Site Number: 8400126 Boston, Massachusetts | |
| Tyler Research Institute, LLC-Site Number: 8400095 Tyler, Texas | |
| UC Davis Health System-Site Number: 8400071 Sacramento, California | |
| UCHealth Digestive Health Center - Anschutz Medical Campus-Site Number: 8400085 Aurora, Colorado | |
| UMass Memorial Medical Center-Site Number: 8400121 Worcester, Massachusetts | |
| UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074 Chapel Hill, North Carolina | |
| United Medical Doctors CA-Site Number: 8400044 Murrieta, California | |
| University Gastroenterology-Site Number: 8400103 Providence, Rhode Island | |
| University Hospitals Cleveland Medical Center-Site Number: 8400073 Cleveland, Ohio | |
| University of Kansas Medical Center-Site Number: 8400110 Kansas City, Kansas | |
| University of Kentucky Hospital/UK Albert B. Chandler Hospital-Site Number: 8400058 Lexington, Kentucky | |
| University of Pennsylvania School of Medicine-Site Number: 8400072 Philadelphia, Pennsylvania | |
| University of Toledo Medical Center-Site Number: 8400042 Toledo, Ohio | |
| Valiance Clinical Research - Tarzana-Site Number: 8400023 Tarzana, California | |
| Valley Institute of Research-Site Number: 8400004 Harlingen, Texas | |
| Velocity Clinical Research, Salt Lake City-Site Number: 8400147 West Jordan, Utah | |
| Virginia Commonwealth University-Site Number: 8400132 Richmond, Virginia | |
| Washington University School of Medicine-Site Number: 8400075 St Louis, Missouri | |
| Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040 New York, New York | |
| Wellness Clinical Research - Vega Baja-Site Number: 8400099 Vega Baja, | |
| Yale University Digestive Disease-Site Number: 8400108 New Haven, Connecticut |
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis (SUNSCAPE-1)
Trial Transparency email recommended (Toll free for US & Canada) - contact-us@sanofi.com
NCT07184996
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to \<18 years of age who meet the definition of Tanner Stage 5 for development
* Confirmed diagnosis of moderately to severely active UC for at least 3 months prior to Baseline
* Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies
Exclusion Criteria:
* Participants with Crohn's Disease (CD), indeterminate colitis
* Current diagnosis of Ulcerative Proctitis
* Participants with surgical bowel resection within the past 3 months prior to Baseline, or a history of \>3 bowel resections
* Prior or current high-grade gastrointestinal (GI) dysplasia
* Participants on treatment with but not on stable doses of conventional therapies prior to baseline
* Participants with prohibited medications or therapies prior to baseline
* Participants with previous exposure to anti-TL1A investigational therapy The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial. DRUG: Duvakitug, DRUG: Placebo
Ulcerative Colitis
I'm interested
Share via email
Show 265 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| 'Sfanta Treime' Municipal Clinical Hospital - Site Number : 4980004 Chisinau, | |
| AdventHealth Orlando - Site Number: 8400070 Orlando, Florida | |
| Alliance Research Institute - Site Number: 8400008 Canoga Park, California | |
| Allied Health Clinical Research Organization, LLC - Freehold - Site Number: 8400014 Freehold, New Jersey | |
| Allied Health Clinical Research Organization, LLC - Jackson - Site Number: 8400007 Jackson, New Jersey | |
| Amicis Research Center-Valencia -Site Number: 8400064 Valencia, California | |
| Aoyama Clinic, Site Number : 3920018 Kobe, | |
| Asahikawa City Hospital - Site Number : 3920011 Asahikawa, | |
| Atlanta Gastroenterology Associates - Site Number: 8400109 Atlanta, Georgia | |
| Atlanta Gastroenterology Specialists - Site Number: 8400149 Suwanee, Georgia | |
| Atlantic Health System, Morristown Medical Center-Site Number: 400137 Morristown, New Jersey | |
| BVL Clinical Research - Site Number: 8400005 Liberty, Missouri | |
| Baylor College of Medicine-Site Number: 8400140 Houston, Texas | |
| Bio Research Partner - Site Number: 8400053 Miami, Florida | |
| Biocentric Health Research Partner West Columbia, South Carolina | |
| Blue Ridge Medical Research - Site Number: 8400020 Lynchburg, Virginia | |
| Blue River Clinical Research-Site Number: 8400160 Kansas City, Missouri | |
| Bukovinian State Medical University - Site Number : 8040003 Chernivtsi, | |
| Care Access - New Iberia - Site Number: 8400031 New Iberia, Louisiana | |
| Cedar Valley Digestive Health Center - Site Number: 8400096 Waterloo, Iowa | |
| Central Sooner Research - Site Number: 8400094 Norman, Oklahoma | |
| Charlton Digestive Disease Centre - Site Number : 1240009 Hamilton, | |
| ClinTrial Research, LLC - Site Number: 8400043 Raleigh, North Carolina | |
| Clinical Applications Laboratories Inc - Site Number: 8400056 San Diego, California | |
| Clinical Hospital Center 'Dr. Dragisa Misovic-Dedinje' - Site Number : 6880007 Belgrade, | |
| Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine, Department of Gastroenterology and Hepatology -Site Number : 6880002 Belgrade, | |
| Clinical Research Partners - Site Number: 8400080 Richmond, Virginia | |
| Clinical Research of Osceola - Site Number: 8400013 Kissimmee, Florida | |
| Clinical Trials Management Services - Site Number: 8400047 Thousand Oaks, California | |
| Columbus Clinical Services LLc - Site Number: 8400038 Miami, Florida | |
| Correa Research Center-Site Number: 8400010 Miami, Florida | |
| Cross Creek Medical Clinic - Site Number: 8400057 Fayetteville, North Carolina | |
| DSI Research, LLC - Site Number: 8400105 Springboro, Ohio | |
| DSI Research, LLC - Site Number: 8400115 Dayton, Ohio | |
| Dayton Gastroenterology, Inc - Dayton-Site Number: 8400166 Dayton, Ohio | |
| Del Sol Research Management, LLC - Site Number: 8400012 Tucson, Arizona | |
| Delta Research Partners Monroe, Louisiana | |
| Duke University Medical Center - Site Number: 8400093 Durham, North Carolina | |
| EBGS Clinical Research Center, LLC - Site Number: 8400037 Snellville, Georgia | |
| Elite Clinical Studies, LLC-Site Number: 8400162 Phoenix, Arizona | |
| Endoskopia Sp. z o.o. (LLC) - Site Number : 6160004 Sopot, | |
| Erick H. Alayo Medical Corporation-Site Number: 8400159 Chula Vista, California | |
| FOMAT - Unio Specialty Care Arcadia - Site Number: 8400027 Arcadia, California | |
| GI Alliance - Baton Rouge - Site Number: 8400129 Baton Rouge, Louisiana | |
| GI Alliance - Bellevue - Site Number: 8400143 Bellevue, Washington | |
| GI Alliance - Glenview - Site Number: 8400068 Glenview, Illinois | |
| GI Alliance - Metairie - Site Number: 8400124 Metairie, Louisiana | |
| GMC Clinical Research, LLC - Site Number: 8400113 Folsom, California | |
| Gastro Health Holdco, LLC-Site Number: 8400024 Maitland, Florida | |
| Gastro One - Cordova-Site Number: 8400158 Cordova, Tennessee | |
| GastroGroup - Site Number: 8400128 Mandeville, Louisiana | |
| Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139 Canton, Ohio | |
| Gastroenterology Associates of Western Michigan - Site Number: 8400060 Wyoming, Michigan | |
| Gastroenterology Health Partners, PLLC - Site Number: 8400100 New Albany, Indiana | |
| Gastroenterology Research of San Antonio LLC - Site Number: 8400054 San Antonio, Texas | |
| Gastroenterology of the Rockies - Denver - Site Number: 8400122 Denver, Colorado | |
| Gateway Gastroenterology - Site Number: 8400097 Chesterfield, Missouri | |
| Grand Teton Research Group, PLLC - Site Number: 8400127 Idaho Falls, Idaho | |
| Hattori Clinic - Site Number : 3920051 Kumamoto, | |
| Henry Ford Medical Center - Columbus-Site Number: 8400118 Novi, Michigan | |
| Hospital du Sacre-Coeur in Montreal-Site Number: 1240007 Montreal, | |
| Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee - Site Number: 8400049 Gurnee, Illinois | |
| Innovare Research Group - Site Number: 8400067 Lake Jackson, Texas | |
| Inquest Clinical Research - Site Number: 8400144 Baytown, Texas | |
| Investigational Site Number : 0320004 Córdoba, | |
| Investigational Site Number : 0360004 Liverpool, | |
| Investigational Site Number : 0360007 Wollongong, | |
| Investigational Site Number : 0400008 Vienna, | |
| Investigational Site Number : 1000001 Sofia, | |
| Investigational Site Number : 1000007 Rusa, | |
| Investigational Site Number : 1000008 Sofia, | |
| Investigational Site Number : 1560001 Chengdu, | |
| Investigational Site Number : 1560003 Wuhan, Hubei | |
| Investigational Site Number : 1560017 Changshu, | |
| Investigational Site Number : 1560023 Nanjing, | |
| Investigational Site Number : 1560033 Wuhan, Hubei | |
| Investigational Site Number : 1560038 Beijing, | |
| Investigational Site Number : 1560039 Luzhou, | |
| Investigational Site Number : 1560040 Zhengzhou, | |
| Investigational Site Number : 1560056 Jinhua, | |
| Investigational Site Number : 1560058 Shanghai, | |
| Investigational Site Number : 1560062 Luoyang, Henan | |
| Investigational Site Number : 1580003 Chiayi City, | |
| Investigational Site Number : 2030002 Slaný, | |
| Investigational Site Number : 2030003 Brno, | |
| Investigational Site Number : 2030011 Hradec Králové, | |
| Investigational Site Number : 2500006 Vandœuvre-lès-Nancy, | |
| Investigational Site Number : 2500010 Lille, | |
| Investigational Site Number : 2500013 Nice, | |
| Investigational Site Number : 2680003 Tbilisi, | |
| Investigational Site Number : 2680005 Tbilisi, | |
| Investigational Site Number : 2680006 Tbilisi, | |
| Investigational Site Number : 2680007 Kutaisi, | |
| Investigational Site Number : 2680008 Tbilisi, | |
| Investigational Site Number : 2760001 Kiel, | |
| Investigational Site Number : 2760003 Berlin, | |
| Investigational Site Number : 2760005 Ulm, | |
| Investigational Site Number : 2760010 Minden, | |
| Investigational Site Number : 2760015 Leipzig, | |
| Investigational Site Number : 2760017 Berlin, | |
| Investigational Site Number : 2760021 Halle, Saxony-Anhalt | |
| Investigational Site Number : 2760024 Erlangen, | |
| Investigational Site Number : 2760026 Herne, | |
| Investigational Site Number : 2760028 Wolfsburg, Lower Saxony | |
| Investigational Site Number : 3480004 Budapest, | |
| Investigational Site Number : 3480005 Eger, | |
| Investigational Site Number : 3800002 Milan, | |
| Investigational Site Number : 3800007 Legnano, | |
| Investigational Site Number : 3800011 Pavia, Lombardy | |
| Investigational Site Number : 3800013 Cagliari, | |
| Investigational Site Number : 3920005 Asahikawa, | |
| Investigational Site Number : 3920008 Okayama, | |
| Investigational Site Number : 3920014 Saga, | |
| Investigational Site Number : 3920015 Toyohashi, | |
| Investigational Site Number : 3920021 Chūō, | |
| Investigational Site Number : 3920023 Sakura, | |
| Investigational Site Number : 3920035 Yokohama, | |
| Investigational Site Number : 3920039 Chikushino-shi, | |
| Investigational Site Number : 3920048 Sendai, | |
| Investigational Site Number : 3920050 Osaka, | |
| Investigational Site Number : 3920056 Sapporo, | |
| Investigational Site Number : 4400001 Kaunas, | |
| Investigational Site Number : 4980003 Chisinau, | |
| Investigational Site Number : 5280001 Nijmegen, | |
| Investigational Site Number : 5540004 Auckland, | |
| Investigational Site Number : 6160002 Szczecin, | |
| Investigational Site Number : 6160005 Warsaw, | |
| Investigational Site Number : 6160006 Warsaw, | |
| Investigational Site Number : 6160009 Warsaw, | |
| Investigational Site Number : 6160012 Wadowice, | |
| Investigational Site Number : 6160013 Elblag, | |
| Investigational Site Number : 6160014 Katowice, | |
| Investigational Site Number : 6160016 Lodz, | |
| Investigational Site Number : 6160018 Poznan, | |
| Investigational Site Number : 6160022 Krakow, | |
| Investigational Site Number : 6160025 Rzeszów, | |
| Investigational Site Number : 6160028 Wrocklaw, | |
| Investigational Site Number : 6160031 Warsaw, | |
| Investigational Site Number : 6880004 Niš, | |
| Investigational Site Number : 7030001 Bratislava, | |
| Investigational Site Number : 7100001 Kempton Park, | |
| Investigational Site Number : 7100004 Durban, | |
| Investigational Site Number : 7100005 Claremont, | |
| Investigational Site Number : 7240003 Santiago de Compostela, | |
| Investigational Site Number : 7560001 Bern, | |
| Investigational Site Number : 7920002 Mersin, | |
| Investigational Site Number : 7920003 Ankara, | |
| Investigational Site Number : 8040013 Kyiv, | |
| Iowa Digestive Disease Center - Site Number: 8400134 Clive, Iowa | |
| Iwate Medical University Hospital - Site Number : 3920020 Shiwa-gun, | |
| Japanese Red Cross Fukuoka Hospital - Site Number : 3920027 Fukuoka, | |
| Kagoshima IBD Gastroenterology Clinic - Site Number : 3920049 Kagoshima, | |
| Kokikai Tsujinaka Hospital Kashiwanoha - Site Number : 3920031 Kashiwa, | |
| LLC The First Medical Center - Site Number : 2680004 Tbilisi, | |
| Las Vegas Clinical Trials - Site Number: 8400079 Las Vegas, Nevada | |
| Lenox Hill Hospital - Site Number: 8400052 New York, New York | |
| Limited Liability Company 'Center of Gastroenterology and Dietology' - Site Number : 8040010 Vinnytsia, | |
| Limited Liability Company 'Edelweiss Medics' - Site Number : 8040001 Kyiv, | |
| Limited Liability Company 'Medbud-Clinic' - Site Number : 8040002 Kyiv, | |
| Limited Liability Company 'PROGASTRO CLINIC' - Site Number : 8040005 Lviv, | |
| M3 Wake Research - Atlanta - Site Number: 8400028 Sandy Springs, Georgia | |
| Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC - Site Number : 2680002 Tbilisi, | |
| Manhattan Clinical Research, LLC - Site Number: 8400069 New York, New York | |
| Mayo Clinic - Jacksonville-Site Number: 8400102 Jacksonville, Florida | |
| MedTraits NY - Site Number: 8400045 Maspeth, New York | |
| Medical Associates Research Group - Site Number: 8400063 San Diego, California | |
| Medical Professional Clinical Research Center - Site Number: 8400119 Miami, Florida | |
| Mercy Medical Center, Baltimore - Site Number: 8400117 Baltimore, Maryland | |
| Mid-Atlantic GI Research, LLC - Site Number: 8400106 Greenbelt, Maryland | |
| Midwest Digestive Health and Nutrition - Site Number: 8400136 Des Plaines, Illinois | |
| Mie University Hospital - Investigational Site Number : 3920009 Tsu, | |
| Monroe Biomedical Research - Site Number: 8400046 Monroe, North Carolina | |
| Montefiore Medical Center - Bronx - Site Number. 8400142 The Bronx, New York | |
| NMC Research LLC - Site Number: 8400033 Tampa, Florida | |
| NYU Langone Health - Site Number: 8400091 New York, New York | |
| Nagaoka Red Cross Hospital - Site Number : 3920041 Nagaoka, | |
| National Center for Global Health and Medicine - Site Number : 3920038 Shinjuku, | |
| National Hospital Organization Kanazawa Medical Center - Investigational Site Number : 3920010 Kanazawa, | |
| National Hospital Organization Osaka National Hospital - Investigational Site Number : 3920002 Osaka, | |
| National Hospital Organization Sendai Medical Center - Investigational Site Number : 3920003 Sendai, | |
| National Pirogov Memorial Medical University - Site Number : 8040008 Vinnytsia, | |
| National Pirogov Memorial Medical University - Site Number : 8040009 Vinnytsia, | |
| National Taiwan University Hospital - Site Number : 1580002 Taipei, | |
| New York Gastroenterology Associates - Site Number: 8400009 New York, New York | |
| New health-CK, Kieltucki and partners g.p. - Site Number : 6160007 Staszów, | |
| North Shore Gastroenterology Research - Site Number: 8400130 Westlake, Ohio | |
| Novum Research, LLC - Site Number: 8400003 Clermont, Florida | |
| OSU Wexner Medical Center - Site Number: 8400077 Columbus, Ohio | |
| Oakville Endoscopy Center Inc. DBA ABP Research Services Corp. - Site Number : 1240010 Oakville, | |
| Ofuna Chuo Hospital - Site Number : 3920029 Kamakura, | |
| Ohio Gastroenterology Group Inc. - Site Number: 8400006 Columbus, Ohio | |
| Om Research, LLC - Lancaster - Site Number: 8400148 Lancaster, California | |
| Om Research, LLC - Oxnard - Site Number: 8400150 Oxnard, California | |
| Om Research, LLC - Victorville - Site Number: 8400022 Victorville, California | |
| OnSite Clinical Solutions - Site Number: 8400051 Charlotte, North Carolina | |
| One of a Kind Clinical Research Center LLC - Site Number: 8400061 Scottsdale, Arizona | |
| One of a Kind Clinical Research Center LLC - Texas - Site Number: 8400125 Kingwood, Texas | |
| Onyx Clinical Research - Site Number: 8400021 Peoria, Arizona | |
| Oregon Health & Science University, Center for Health and Healing 2 - Site Number: 8400131 Portland, Oregon | |
| Orlando Health, Inc. - Site Number: 8400084 Orlando, Florida | |
| PMSI 'Timofei Mosneaga' Republican Clinical Hospital - Site Number : 4980002 Chisinau, | |
| Paradisus Med Research - Site Number: 8400036 Miami, Florida | |
| Peak Gastroenterology Associates - Colorado Springs - Site Number: 8400039 Colorado Springs, Colorado | |
| Penn State Milton S. Hershey Medical Center - Site Number: 8400066 Hershey, Pennsylvania | |
| Plains Medical Clinic - Site Number: 8400078 Fargo, North Dakota | |
| Precision Clinical Research-Site Number: 8400059 Coral Springs, Florida | |
| Preferred Research Partners - Site Number: 8400018 Little Rock, Arkansas | |
| Premier Health Research, LLC - Site Number: 8400114 Sparta, New Jersey | |
| Public Institution Panevezys Republican hospital - Site Number : 4400002 Panevezys, | |
| Public Non-Profit Enterprise 'Andrii Novak Zakarpattia Regional Clinical Hospital' under Zakarpattia Regional Council - Site Number : 8040006 Uzhhorod, | |
| Puerto Rico Health and Wellness Institute - Site Number: 8400104 Dorado, | |
| Regis Clinical Research, LLC - Site Number: 8400041 Miami, Florida | |
| Rush University Medical Center - Site Number: 8400015 Chicago, Illinois | |
| SMS Clinical Research - Site Number: 8400035 Mesquite, Nevada | |
| SONOMED - Site Number : 6160020 Szczecin, | |
| SUNY Upstate Medical University-Site Number: 8400156 Syracuse, New York | |
| Sanmora Bespoke Clinical Research Solutions LLC - Site Number: 8400123 East Orange, New Jersey | |
| Santa Maria Gastroenterology - FOMAT Medical Research HyperCORE - Site Number: 8400025 Santa Maria, California | |
| Sapporo Higashi Tokushukai Hospital - Investigational Site Number : 3920042 Sapporo, | |
| Sapporo Tokushukai Hospital - Site Number : 3920019 Sapporo, | |
| Sarkis Clinical Trials-Ocala - Site Number: 8400048 Gainesville, Florida | |
| Scottsdale Clinical Trials - Site Number: 8400145 Scottsdale, Arizona | |
| Southern California GI & Liver Centers - Site Number: 8400062 Coronado, California | |
| State Non-Profit Enterprise 'Danulo Halytsky National Medical University in Lviv' - Site Number : 8040012 Lviv, | |
| Sylvester Comprehensive Cancer Center - A University of Miami Hospital and Clinics Facility - Miami - Site Number: 8400111 Miami, Florida | |
| TLC Clinical Research Inc. - Site Number: 8400030 Los Angeles, California | |
| Takagi Clinic - Site Number : 3920004 Sendai, | |
| Tandem Clinical Research - Marrero - Site Number: 8400002 Marrero, Louisiana | |
| Tandem Intermediate, LLC - Houma -Site Number: 8400034 Houma, Louisiana | |
| Tandem-Allied Clinical Research - Somers Point - Site Number: 840050 Somers Point, New Jersey | |
| Texas Digestive Disease Consultants dba GI Alliance - Lubbock - Site Number: 8400092 Lubbock, Texas | |
| Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake - Site Number: 8400101 Southlake, Texas | |
| Texas Gastro Consultants - Site Number: 8400029 Tomball, Texas | |
| The Allegheny Health Network (AHN) Center for Digestive Health - Site Number: 8400107 Pittsburgh, Pennsylvania | |
| The University of Texas Southwestern Medical Center - Site Number: 8400098 Dallas, Texas | |
| The University of Tokyo Hospital - Site Number : 3920059 Bunkyō City, | |
| The Vancouver Clinic Inc. P.S. - Site Number: 8400090 Vancouver, Washington | |
| Tokai University Hachioji Hospital - Site Number : 3920030 Tokyo, | |
| Toronto Immune and Digestive Health Institute Inc. (TIDHI) - Site Number : 1240003 Toronto, | |
| Toyama Prefectural Central Hospital - Site Number : 3920037 Toyama, | |
| Toyama University Hospital - Site Number : 3920032 Toyama, | |
| Tropical Clinical Trials - Site Number: 8400082 Palmetto Bay, Florida | |
| Tufts Medical Center - Site Number: 8400126 Boston, Massachusetts | |
| Tyler Research Institute, LLC - Site Number: 8400095 Tyler, Texas | |
| UC Davis Health System - Site Number: 8400071 Sacramento, California | |
| UCHealth Digestive Health Center - Anschutz Medical Campus - Site Number: 8400085 Aurora, Colorado | |
| UMass Memorial Medical Center - Site Number: 8400121 Worcester, Massachusetts | |
| UNC Hospitals, The University of North Carolina at Chapel Hill - Site Number: 8400074 Chapel Hill, North Carolina | |
| United Medical Doctors CA - Site Number: 8400044 Murrieta, California | |
| University Clinical Center of Serbia - Site Number : 6880006 Belgrade, | |
| University Gastroenterology - GI Alliance - Site Number: 8400103 Providence, Rhode Island | |
| University Hospital of the State Non-Profit Enterprise 'Danylo Halytsky Lviv National Medical University' - Site Number : 8040004 Lviv, | |
| University Hospitals Cleveland Medical Center-Site Number: 8400073 Cleveland, Ohio | |
| University of Kansas Medical Center - Site Number: 8400110 Kansas City, Kansas | |
| University of Kentucky Hospital/UK Albert B. Chandler Hospital - Site Number: 8400058 Lexington, Kentucky | |
| University of Pennsylvania School of Medicine - Site Number: 8400072 Philadelphia, Pennsylvania | |
| University of Toledo Medical Center - Site Number: 8400042 Toledo, Ohio | |
| Valiance Clinical Research - Tarzana - Site Number: 8400023 Tarzana, California | |
| Valley Institute of Research - Site Number: 8400004 Harlingen, Texas | |
| Velocity Clinical Research, Salt Lake City - Site Number: 8400147 West Jordan, Utah | |
| Virginia Commonwealth University-Site Number: 8400132 Richmond, Virginia | |
| Weill Cornell Medical College - NewYork-Presbyterian Hospital - Site Number: 8400040 New York, New York | |
| Wellness Clinical Research - Vega Baja - Site Number: 8400099 Vega Baja, | |
| Yale University Digestive Disease - Site Number: 8400108 New Haven, Connecticut | |
| Zvezdara University Medical Center, Clinic of Internal Diseases, Clinical Department of Gastroenterology and Hepatology -Site Number : 6880001 Belgrade, |